ZYUS Life Sciences Corporation

ZYUS LIFE SCIENCES CORP's next confirmed earnings release is scheduled for November 26, 2026.

As of June 30, 2026, ZYUS LIFE SCIENCES CORP has 80.52M shares outstanding.

As of June 30, 2026, ZYUS LIFE SCIENCES CORP maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -88.40, indicating conservative leverage, while an interest coverage ratio of -4.45 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -239.03, reflecting losses generated across the asset base. Inventory turnover of 1.00 indicates how many times ZYUS LIFE SCIENCES CORP sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 21, 2026, ZYUS LIFE SCIENCES CORP's stock has gained approximately 11.11% over the past 52 weeks.

Over the twelve months ended June 30, 2026, ZYUS LIFE SCIENCES CORP generated 263,526.89 in revenue and converted that into -13.71M in net income, yielding earnings per share of -0.17. EBITDA reached -10.10M, while operating income came in at -7.97M.

As of June 30, 2026, ZYUS LIFE SCIENCES CORP holds 142,332.71 in cash and equivalents against 16.80M in total debt, resulting in a net debt position of 15.25M. Total book value stands at -19.00M, with working capital of -15.43M providing operational flexibility.

ZYUS LIFE SCIENCES CORP produced -5.00M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7,750.79 in capital expenditures, free cash flow totaled -5.01M - equivalent to -0.06 per share.

Over the twelve months ended June 30, 2026, ZYUS LIFE SCIENCES CORP posted a gross margin of 1.34, reflecting its pricing power and cost economics. The operating margin of -3,022.99 and net profit margin of -5,202.41 provide insight into operational efficiency.